Indications and Purposes
| 1 Indications And Usage Dovato Is Indicated As A Complete Regimen For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Adults With No Antiretroviral Treatment History Or To Replace The Current Antiretroviral Regimen In Those Who Are Virologically Suppressed (Hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen With No History Of Treatment Failure And No Known Substitutions Associated With Resistance To The Individual Components Of Dovato. Dovato, A Two-Drug Combination Of Dolutegravir (Integrase Strand Transfer Inhibitor [Insti]) And Lamivudine (Nucleoside Analogue Reverse Transcriptase Inhibitor [Nrti]) Is Indicated As A Complete Regimen For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Adults With No Antiretroviral Treatment History Or To Replace The Current Antiretroviral Regimen In Those Who Are Virologically Suppressed (Hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen With No History Of Treatment Failure And No Known Substitutions Associated With Resistance To The Individual Components Of Dovato. ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 2 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Dolutegravir Sodium |
|
ZINC58581064 |
| 2. Lamivudine |
|
ZINC12346 |